NFA
NBSE

Nationwide Fund Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Nationwide Fund Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-38
Closed -$39K – 3362
2015
Q1 		$39K Sell
38
-2
-5% -$6.6K ﹤0.01% 3129
2014
Q4 		$134K Hold
40
– – ﹤0.01% 2823
2014
Q3 		$117K Hold
40
– – ﹤0.01% 2926
2014
Q2 		$151K Buy
+40
New +$151K ﹤0.01% 2874

Other funds holding NBSE

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nationwide Fund Advisors's NBSE Position: Q2 2015 in Review

Nationwide Fund Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2015, closing a stake of 38 shares — an estimated $39K sold.

Nationwide Fund Advisors first reported a position in NBSE in Q2 2014 and held it in 4 quarters. The position peaked at $151K in Q2 2014. 66 funds tracked by Wall St. Rank hold NBSE as of Q2 2015.

  • Nationwide Fund Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Nationwide Fund Advisors sold 38 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $39K.
  • Nationwide Fund Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 4 quarters.
  • Nationwide Fund Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $151K in Q2 2014.
  • 66 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Nationwide Fund Advisors's 13F filing for Q2 2015, filed 29 Jul 2015.